<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04175470</url>
  </required_header>
  <id_info>
    <org_study_id>BeTo-Ovar</org_study_id>
    <nct_id>NCT04175470</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer</brief_title>
  <official_title>Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer: A Marker Based Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vejle Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A recent study at the Department of Oncology, Vejle Hospital (NCT02399592), investigated&#xD;
      bevacizumab and tocotrienol in ovarian cancer patients and concurrently monitored the level&#xD;
      of methylated HOXA9 circulating tumor DNA (HOXA9 meth-ctDNA) in the blood.&#xD;
&#xD;
      The rate of disease control was 70% with better results than other studies using bevacizumab&#xD;
      alone. The toxicity was very low and attributed to bevacizumab only.&#xD;
&#xD;
      When the study results were worked up they showed that patients with a significant increase&#xD;
      of HOXA9 meth-ctDNA after the first cycle of treatment did not benefit from the treatment&#xD;
      whereas those with stable or decreasing HOXA9 meth-ctDNA did.&#xD;
&#xD;
      Therefore, in the current study patients with a high increase of HOXA9 meth-ctDNA after the&#xD;
      first treatment cycle will discontinue treatment, as it is then considered ineffective. The&#xD;
      remaining patients may achieve prolonged survival as predicted by their level of HOXA9&#xD;
      meth-ctDNA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2019</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>6 months after enrollment of the last patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months after enrollment of the last patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate as measured by RECIST 1.1 or CA-125</measure>
    <time_frame>6 months after enrollment of the last patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by CTC version 5.0</measure>
    <time_frame>Every 9 weeks until progression, up to 3 years</time_frame>
    <description>CTC = National Cancer Institute's Common Toxicity Criteria (NCI-CTC)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ovarian Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Arm A: Discontinue treatment after first treatment cycle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Continue treatment until progression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>10 mg/kg intravenously every three weeks</description>
    <arm_group_label>Arm A: Discontinue treatment after first treatment cycle</arm_group_label>
    <arm_group_label>Arm B: Continue treatment until progression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Tocotrienol</intervention_name>
    <description>Capsules, 300 mg orally three times daily</description>
    <arm_group_label>Arm A: Discontinue treatment after first treatment cycle</arm_group_label>
    <arm_group_label>Arm B: Continue treatment until progression</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed epithelial ovarian cancer, primary fallopian or primary&#xD;
             peritoneal cancer.&#xD;
&#xD;
          -  Platinum resistant epithelial ovarian cancer treated with at least two different&#xD;
             previous chemotherapeutic regimens&#xD;
&#xD;
          -  Progression on previous treatment. Previous treatment with bevacizumab is allowed.&#xD;
&#xD;
          -  Measurable disease by the RECIST 1.1 criteria or evaluable by the GCIG CA-125&#xD;
             criteria.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Performance status 0-2.&#xD;
&#xD;
          -  Adequate bone marrow function, liver function, and renal function (within 7 days prior&#xD;
             to inclusion):&#xD;
&#xD;
               -  WBC ≥ 3.0 x 10^9/l or neutrophils (ANC) ≥ 1.5 x 10^9/l&#xD;
&#xD;
               -  Platelet count ≥ 100 x 10^9/l&#xD;
&#xD;
               -  Hemoglobin ≥ 6 mmol/l&#xD;
&#xD;
               -  Serum bilirubin &lt; 2.0 x ULN&#xD;
&#xD;
               -  Serum transaminase ≤ 2.5 x ULN&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 ULN&#xD;
&#xD;
          -  Urine dipstick for protein &lt; 2+. If the dipstick shows protein ≥ 2+, 24 hour urine&#xD;
             testing must be performed and show protein contents &lt; 1 g.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other malignant disease within 3 years prior to inclusion in the study, except&#xD;
             curatively treated basal cell or squamous cell carcinoma of the skin.&#xD;
&#xD;
          -  Other experimental therapy or participation in another clinical trial within 28 days&#xD;
             prior to treatment initiation.&#xD;
&#xD;
          -  Intestinal infiltration or infiltration in major blood vessels at the discretion of&#xD;
             the treating physician.&#xD;
&#xD;
          -  Underlying medical disease not adequately treated (diabetes, cardiac disease).&#xD;
&#xD;
          -  Uncontrolled hypertension (BP &gt; 150/100 despite antihypertensive treatment).&#xD;
&#xD;
          -  Surgery including open biopsy, within 4 weeks prior to first dose of bevacizumab.&#xD;
&#xD;
          -  Cerebral vascular attack, transient ischemic attack or subarachnoid hemorrhage within&#xD;
             6 months before start of treatment.&#xD;
&#xD;
          -  Clinical significant cardiovascular disease, including:&#xD;
&#xD;
               -  Myocardial infarction or unstable angina within 6 months before start of&#xD;
                  treatment&#xD;
&#xD;
               -  New York Heart Association (NYHA) class ≥ 2&#xD;
&#xD;
               -  Poorly controlled cardiac arrhythmia despite medication&#xD;
&#xD;
               -  Peripheral vascular disease grade ≥ 3&#xD;
&#xD;
          -  Allergy to active substance or any of the auxiliary agents&#xD;
&#xD;
          -  Bleeding tumor&#xD;
&#xD;
          -  Pregnant or breast-feeding patients. For fertile women a negative pregnancy test at&#xD;
             screening is mandatory.&#xD;
&#xD;
          -  Fertile patients not willing to use effective methods of contraception during&#xD;
             treatment and for 6 months after the end of treatment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karina D Steffensen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology, Vejle Hospital - University Hospital of Southern Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Louise Faaborg, MD</last_name>
    <phone>+45 7940 5446</phone>
    <email>louise.faaborg.larsen@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Oncology, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Faaborg, MD</last_name>
      <email>louise.faaborg.larsen@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

